



Your partner in topical drug delivery and formulation

Press Release

For immediate release

Date: 2nd April 2009

MedSpray® ‘Patch in a Can®’ technology successfully completes Phase II clinical evaluation in Athlete’s foot.

MedPharm has announced that its MedSpray® technology has completed its phase II clinical evaluation. The trial was a Phase II non-inferiority study comparing TerbiMed™ against a market-leading European commercial treatment.

The aim of the Phase II study was to show efficacy with a short dosing regime, however one of the main advantages is the product’s ‘elegance’ which will make it more user friendly for patients. TerbiMed™ product produces a film which resides on the skin and does not require any further manipulation by the patient. The top-line data shows that the aims of the trial were successfully achieved.

MedSpray® is a platform drug delivery technology that provides a sprayable pharmaceutical formulation capable of forming a microthin film on topical administration on or in the skin. It has the dual advantages of being able to enhance and sustain the delivery of drugs whilst being easily applied and where necessary removed. The presentation and properties of the spray and film can be manipulated according to drug, disease and site of application

MedPharm CSO and co-inventor of the MedSpray® technology, Prof. Marc Brown, said “The success of our clinical trial is very exciting news for two reasons: it validates the MedSpray® drug delivery technology and has demonstrated that MedPharm has developed a topical medicine for the treatment of athlete’s foot that is safe and efficacious and could be commercialised globally. I also believe this clinical

data will provide the foundation for investigation into numerous other topical and transdermal applications”.

MedSpray® is the first of several new concepts to emerge from MedPharm's research and development centre in Guildford, which also include MedNail®, a patented nail penetration system, MedRo™ and MedTherm™’.

Further transdermal uses for the technology could include antihistamine delivery, hormone replacement therapy, nicotine delivery, treatment for angina or nasal infections. Meanwhile local indications could include delivery of anti-inflammatories and treatment of psoriasis.

MedPharm is a fee of service topical pharmaceutical development company which also develops new concepts in drug delivery, is inviting pharmaceutical companies to make use of the technology. The company has recently announced its first licensing agreement for the MedSpray® technology with Moberg Derma AB and is seeking additional licensing partners who have a suitable drug as well as the financial resource to enable clinical development, registration, and marketing.

For more information including interviews with Medpharm CEO Andrew Muddle or the development team, please contact Beth Schuten +44 1483 447740 or email info@medpharm.co.uk

About MedPharm is a specialist pharmaceutical development company that is recognized internationally, particularly for its expertise in topical (skin, nail, mucous membranes) and airway delivery systems. Established in 1999 and with over 60 customers worldwide, MedPharm has build a reputation for its unique and highly specialized service in contract research and development, together with expert project management. Projects range from simple feasibility tests, dosage design and optimization, through to preparation of GMP clinical supplies for Phase I/II trials with guaranteed smooth transfer through to manufacturing sites. MedPharm has GLP accredited laboratories in Guildford Surrey, UK and a GMP facility in the South of England.

The company has a substantial patent portfolio of novel drug delivery systems, some of which, for example in topical formulations, it is exploiting in its internal drug development programme. These technologies are also available, either as part of the service offering or as stand-alone licences, to third parties for developing their own compounds in non-competing indications. In addition, MedPharm is actively seeking to license out that IP, for example, in novel formulations for pulmonary drug delivery, for which it is planning no further internal development.

Address: MedPharm R&D centre, Unit 3, Chancellor Court, 50 Occam Road, Surrey Research Park, Guildford, Surrey, GU27YN.

More information can be found at www.medpharm.co.uk

About MedSpray®

MedSpray® is a patented self-assembling Patch in a Can® technology which optimizes topical and transdermal drug delivery by overcoming the barrier properties of the stratum corneum. MedSpray® provides a sprayable pharmaceutical formulation capable of forming a microthin film on topical administration that simply washes off after use, if required. The properties of the film can be manipulated to achieve the required drug delivery and film properties in terms of tackiness, viscosity and water resistance.